MiNK Therapeutics, Inc. has announced the appointment of Melissa Orilall as the new Principal Financial Officer, effective March 13, 2026. Orilall, who previously served as Vice President of Global Financial Operations at Agenus Inc., will provide her services to MiNK through an intercompany services agreement. At Agenus, she has been responsible for overseeing general accounting and financial planning since joining the company in 2017. Additionally, Austin Charette has been appointed as the Principal Accounting Officer. Charette, who has been with Agenus since 2017, will also serve MiNK under the same intercompany agreement. Both appointments are expected to enhance the financial oversight and operational execution of MiNK Therapeutics as it continues to navigate its growth trajectory in the biotechnology sector. Notably, there were no new arrangements or modifications to existing arrangements for either officer in connection with their appointments, and they will not receive direct compensation from MiNK for their services. This strategic leadership change is anticipated to positively influence the company's financial management and operational execution moving forward.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.